At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 110 target
Drug / intervention
LBL-024 for Injection +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 04]
In Brief
A Phase 2 clinical trial evaluating LBL-024 for Injection, Capecitabine tablets, and 2 other interventions for Advanced Solid Tumour. Currently recruiting, targeting 110 participants across 7 sites.
Detailed Summary
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumour
CountriesChina
CollaboratorsPeking University Cancer Hospital & Institute
Timeline
Phase 2Recruiting
202620272028
First PostedFeb 2026
Enrollment StartApr 2026
TodayJul 2026
Primary CompletionMay 2028
First PostedFeb 5, 2026
Enrollment StartApr 13, 2026
Primary CompletionMay 30, 2028
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 5 months agoPrimary completion in 1.9 years
Interventions
LBL-024 for Injectiondrug
Intravenous infusion
Capecitabine tabletsdrug
Oral administration
Tislelizumab Injectiondrug
Intravenous infusion
Oxaliplatin injectiondrug
Intravenous infusion